Cogent Biosciences, Inc.
COGTHealthcareNASDAQBiotechnology · Last scanned Jul 15, 2026
Scan Results
Daily timeframePart of the healthcare sector, Cogent Biosciences, Inc. (COGT) is listed under Biotechnology. At a $6.58B market cap, Cogent Biosciences, Inc. ranks as a mid-cap company within healthcare. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
Market Cap
$6.58B
Beta
0.34
P/E (TTM)
—
P/E (Fwd)
-40.29
EPS (TTM)
$-2.23
EPS (Fwd)
$-0.96
ROE
-85.7%
ROA
-38.1%
Cash
$866.4M
Total Debt
$238.7M
Free CF
-$167.3M
52W Change
225.7%
Annual Financials
Cash vs Debt
With $866.4M in cash and $238.7M in debt, COGT maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$167.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -85.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
COGT's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, COGT has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Cogent Biosciences, Inc.'s trajectory.